REFERENCES
- Lythgoe MP, Middleton P. Ongoing clinical trials for the management of
the COVID-19 pandemic, trends in pharmacological sciences (2020).
- Liu C, Zhou Q, Li Y, et.al.
Research and
development on therapeutic agents and vaccines for COVID-19 and
related human coronavirus diseases. ACS Cent Sci .
2020;6(3):315-331.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults
hospitalized with severe COVID-19. N Engl J Med .
2020;NEJMoa2001282.
- Chen ZW, Hu JJ, Zhang ZW, et al. Efficacy of hydroxychloroquine in
patients with COVID-19: results of a randomized clinical trial.medRxiv . 2020.
- Kalil AC. Treating COVID-19-Off-Label drug use, compassionate use, and
randomized clinical trials during pandemics. JAMA . 2020.
- Woodcock J, LaVange LM. Master protocols to study multiple therapies,
multiple diseases, or both. N Engl J Med . 2017;377(1):62-70..
- Welliver R, Monto AS, Carewicz O, et.al.
Effectiveness of
oseltamivir in preventing influenza in household contacts: a
randomized controlled trial. JAMA. 2001;285(6):748-54.
- World Health Organization, & World Health Organization. (2020).
Report of the who-china joint mission on coronavirus disease 2019
(covid-19). Available on-line: https://www. who.
int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.
pdf.
- Mizumoto K, Kagaya K, Zarebski A, et.al.
Estimating the
asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases
on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.Euro Surveill . 2020;25(10):2000180.
- Wang Y, Liu Y, Liu L, et.al. Clinical outcome of 55 asymptomatic cases
at the time of hospital admission infected with SARS-Coronavirus-2 in
Shenzhen. China. J Infect Dis . 2020.
- Wu Z and McGoogan JM. Characteristics of and important lessons from
the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of
a report of 72 314 cases from the Chinese center for disease control
and prevention. JAMA . 2020.
- Onder G, Rezza G, Brusaferro S.
Case-Fatality rate
and characteristics of patients dying in relation to COVID-19 in
Italy. JAMA . 2020.
- Novel
Coronavirus Pneumonia Emergency Response Epidemiology Team. The
epidemiological characteristics of an outbreak of 2019 novel
coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing
Bing Xue Za Zhi . 2020;41(2):145-151.
- United
Nations, Department of Economic and Social Affairs, Population
Division (2019). World Population Prospects 2019: Volume I:
Comprehensive Tables. Available on
line:https://population.un.org/wpp/Publications/Files/WPP2019_Volume-I_Comprehensive-Tables.pdf.
- Severe Outcomes Among Patients with Coronavirus Disease 2019
(COVID-19) — United States, February 12–March 16, 2020. MMWR Morb
Mortal Wkly Rep. 2020;69:343-346.
- O’Dwyer DN, Dickson RP, Moore BB.
The lung microbiome,
lmmunity, and the pathogenesis of chronic lung disease. J
Immunol . 2016;196(12):4839-47.
- Loverdos K, Bellos G, Kokolatou L, et.al.
Lung microbiome in
asthma: current perspectives. J Clin Med . 2019;8(11):1967.
- Coutard B, Valle C, de Lamballerie X, et.al.
The spike
glycoprotein of the new coronavirus 2019-nCoV contains a furin-like
cleavage site absent in CoV of the same clade. Antiviral Res .
2020;176:104742.
- Matsuyama S, Nao N, Shirato K, et.al.
Enhanced
isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl
Acad Sci U S A . 2020;117(13):7001-7003.
- Ferrario CM, Jessup J, Chappell MC, et al. Effect of
angiotensin-converting enzyme inhibition and angiotensin II receptor
blockers on cardiac angiotensin-converting enzyme 2.Circulation . 2005;111(20):2605-10.
- Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers: What Is the Evidence?JAMA . 2020.
- Coronaviridae Study Group of the International Committee on Taxonomy
of Viruses. The species Severe acute respiratory syndrome-related
coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat
Microbiol. 2020;5(4):536–544.
- Chen L, Xiong J, Bao L, et.al. Convalescent plasma as a potential
therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400.
- van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of
convalescent plasma for Ebola virus disease in Guinea. N Engl J
Med. 2016;374(1):33-42.
- Burnouf T, Radosevich M. Treatment of severe acute respiratory
syndrome with convalescent plasma. Hong Kong Med J.2003;9(4):309.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients
with COVID-19 with convalescent plasma. JAMA. 2020;e204783.
- Zhang L, Liu Y. Potential interventions for novel coronavirus in
China: A systematic review. J Med Virol. 2020;92(5):479–490.
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry
Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor. Cell. 2020 S0092-8674(20)30229-4.
- Wang K, Chen W, Zhou YS, et al. SARS-CoV-2 invades host cells via a
novel route: CD147-spike protein. bioRxiv . 2020.
- Ibrahim IM, Abdelmalek DH, Elshahat ME, et.al. COVID-19 spike-host
cell receptor GRP78 binding site prediction. J Infect . 2020.
- Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of
SARS-CoV-2 on virus entry and its immune cross-reactivity with
SARS-CoV. Nat Commun . 2020;11(1):1620.
- Wang PH, Cheng Y. Increasing host cellular
receptor—angiotensin-converting enzyme 2 (ACE2) expression by
coronavirus may facilitate 2019-nCoV infection. bioRxiv . 2020.
- Simmons G, Bertram S, Glowacka I, et al. Different host cell proteases
activate the SARS-coronavirus spike-protein for cell–cell and
virus–cell fusion. Virology . 2011; 413:265-74.
- Devaux CA, Rolain JM, Colson P, et.al. New insights on the antiviral
effects of chloroquine against coronavirus: what to expect for
COVID-19? Int J Antimicrob Agents. 2020;105938.
- Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential
treatment for 2019-nCoV acute respiratory disease. Lancet .
2020;395(10223): e30-e31.
- Wang ML, Cao RY, Zhang LK, et al. Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus (2019-nCoV)
in vitro. Cell Res . 2020;30(3):269-271.
- Sheahan TP, Sims AC, Graham RL, et.al.
Broad-spectrum
antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.Sci Transl Med . 2017;9(396):eaal3653.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and
projection of optimized dosing design of hydroxychloroquine for the
treatment of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Clin Infect Dis . 2020.
- Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial
of Ebola virus disease terapeutics. N Engl J Med .
2019;381(24):2293-2303.
- de Wit E, Feldmann F, Cronin J, et.al.
Prophylactic and
therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model
of MERS-CoV infection. Proc Natl Acad Sci U S A .
2020;117(12):6771-6776.
- Adelusi SA, Salako LA. Kinetics of the distribution and elimination of
chloroquine in the rat. Gen Pharmacol . 1982;13:433-437.
- McChesney EW. Animal toxicity and pharmacokinetics of
hydroxychloroquine sulfate. Am J Med . 1983;75(1A):11-8.
- Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and
control of COVID-19. Viruses . 2020;12(4).
- Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of
hospitalized patients with COVID-2019. Nature . 2020.
- McLean HQ, Belongia EA, Kieke BA, et al. Impact of late oseltamivir
treatment on influenza symptoms in the outpatient setting: results of
a randomized trial. Open Forum Infect Dis . 2015;2(3):ofv100.
- Gao JJ, Tian ZX, Yang X. Breakthrough: Chloroquine phosphate has shown
apparent efficacy in treatment of COVID-19 associated pneumonia in
clinical studies. Biosci Trends . 2020;14(1):72-73.
- Multicenter collaboration group of Department of Science and
Technology of Guangdong Province and Health Commission of Guangdong
Province for chloroquine in the treatment of novel coronavirus
pneumonia. Expert consensus on chloroquine phosphate for the treatment
of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za
Zhi . 2020;12;43(3):185-188.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and
azithromycin as a treatment of COVID-19: results of an open label
non-randomized clinical trial. Int J Antimicrob Agents . 2020.
- Chen J, Liu DP, Liu L, et al. A pilot study of hydroxychloroquine in
treatment of patients with common coronavirus disease-19 (COVID-19).Journal of ZheJiang University . 2020.
- Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological
effect of a combination of hydroxychloroquine and azithromycin in 80
COVID-19 patients with at least a six-day follow up: A pilot
observational study. Travel Med Infect D . 2020.
- Bi QF, Wu YS, Mei SJ , et al. Epidemiology and transmission of
COVID-19 in Shenzhen China: analysis of 391 cases and 1286 of their
close contacts. medRxiv . 2020.
- Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19
transmission. Lancet Glob Health . 2020.
- Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel
coronavirus in the United States. N Engl J Med .
2020;5;382(10):929-936.
- Warren TK, Jordan R, Lo MK, et al Therapeutic efficacy of the small
molecule GS-5734 against Ebola virus in rhesus monkeys. Nature .
2016;17;531(7594):381-385.
- Grein J, Ohmagari N, Shin D. et.al. Compassionate use of remdesivir
for patients with severe COVID-19. N Engl J Med . 2020.
- Wu C, Chen X, Cai Y, et al. Risk factors associated with acute
respiratory distress syndrome and death in patients with coronavirus
disease 2019 pneumonia in Wuhan, China. JAMA Intern Med . 2020.
- Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the
treatment of SARS: initial virological and clinical findings.Thorax . 2004;59(3):252-256.
- To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in
posterior oropharyngeal saliva samples and serum antibody responses
during infection by SARS-CoV-2: an observational cohort study.Lancet Infect Dis . 2020.
- Madelain V, Nguyen T HT, Olivo A, et al. Ebola virus Infection: review
of the pharmacokinetic and pharmacodynamic properties of drugs
considered for testing in human efficacy trials. J Clinical
Pharmacokinetics . 2016;55(8):907-923.
- Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir
for COVID-19: an Open-label control Study. Engineering . 2020.
- Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of
severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist
tocilizumab may be the key to reduce the mortality. Int J
Antimicrob Agents . 2020;105954.